



Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide

Giorgia Urbinati, Isabelle I. de Waziers, Mateja Slamić, Tobias Foussigniere, Hafiz Ali, Didier Desmaële, Patrick Couvreur, Liliane Massaad-Massade

► To cite this version:

Giorgia Urbinati, Isabelle I. de Waziers, Mateja Slamić, Tobias Foussigniere, Hafiz Ali, et al.. Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide. *Molecular Therapy - Nucleic Acids*, 2016, 5, pp.e301. <10.1038/mtna.2016.16>. <hal-02329823>

HAL Id: hal-02329823

<https://hal.science/hal-02329823v1>

Submitted on 22 Dec 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide

Giorgia Urbinati¹, Isabelle de Waziers², Mateja Slamić¹, Tobias Foussignière¹, Hafiz M Ali^{1,3}, Didier Desmaële⁴, Patrick Couvreur⁴ and Liliane Massaad-Massade¹

Our purpose was to develop a new pharmacological approach for the treatment of prostate cancer (PCa), the most common neoplasia in men. Recently, we developed siRNA against the fusion oncogene *TMPRSS2-ERG* found in 50% of patients and showed an antitumoral activity in animal model. Herein, we want to compare or combine the developed siRNA to flutamide (FLU), one of the gold-standard treatment of PCa. Therefore, concomitant or subsequent association of FLU to siRNA *TMPRSS2-ERG* was performed in VCaP cells and in SCID mice bearing xenografted VCaP tumors. *ERG*, androgen receptor, cleaved-caspase-3 as well as phase 1 and 2 drug-metabolizing enzymes were investigated within tumors. We observed similar results in terms of *TMPRSS2-ERG* knock-down and cell viability impairment for all distinct schedules of administration. The association of siRNA *TMPRSS2-ERG*-squalene nanoparticles with flutamide displayed similar tumor growth inhibition as mice treated with siRNA *TMPRSS2-ERG*-squalene nanoparticles alone and was paralleled with modification of expression of *ERG*, androgen receptor, and cleaved-caspase-3. Phase 1 and 2 enzymes were essentially affected by FLU and reverted when combined with squalenoylated siRNA. In conclusion, these results confirm the therapeutic effectiveness of squalenoyl siRNA nanomedicine for PCa based on siRNA *TMPRSS2-ERG*.

Molecular Therapy—Nucleic Acids (2016) 5, e301; doi:10.1038/mtna.2016.16; published online 29 March 2016

Subject Category: siRNA, shRNA and miRNAs; Therapeutic proof of concept

Introduction

Nowadays, prostate cancer (PCa) is the most common neoplasia in males in Western countries (43%) representing the fourth leading cause of cancer-related deaths in men and its incidence steadily increases worldwide.^{1,2} Generally, for localized PCa, patients undertake ablative surgery and/or radiotherapy.³ For recurrent malignancy, the androgen deprivation therapy, based on the association of multidrugs reducing male hormones, or the antiandrogen monotherapy are the first-line treatments based on the driving role of the androgen receptor (AR) in the onset and progression of this pathology which is often hormone dependent.⁴ Several approaches have been applied mainly based on decreasing testosterone levels or via AR antagonists to suppress AR signaling pathway. Since 1989, flutamide (FLU) is considered the gold standard nonsteroidal antiandrogen therapy able to antagonise androgen binding to its receptor and its shuttling into the nucleus, thus destroying overall the AR signaling pathway.^{5,6} However, FLU is responsible for several side effects provoking discontinuation of treatment for excessive toxicity. Hence, new molecules with similar antiandrogen activities have been developed such as bicalutamide, nilutamide, and more recently enzalutamide, nevertheless, their toxicological profile is very similar to FLU.⁶ Moreover, despite the undeniable effectiveness and benefits derived from androgen deprivation therapy or antiandrogen monotherapy, most of the patients relapse after few years of antihormonal treatment, and the disease progresses into a castration-resistant form.⁷

Therefore, there is an urgent need for new strategies based on novel targets or innovative combination therapies.

With the purpose of developing new pharmacological approaches for the treatment of PCa, the fusion oncogene *TMPRSS2-ERG*, described by Tomlins *et al.*⁸ in 2005, seems to be a relevant candidate for more specific therapy, such as small interfering RNA (siRNA). *TMPRSS2-ERG* fusion oncogene is not only detected in 50% of PCa biopsies but also in metastasis supporting the relevance of the oncogene in tumor development and progression.^{9,10} *TMPRSS2-ERG* is the consequence of translocation or interstitial deletion in chromosome 21q22 that fuses the 5'-untranslated region of *TMPRSS2*, carrying androgen-responsive elements, with the encoding region of the oncogenic *ETS* transcription factor, *ERG*. As a result, *TMPRSS2* drives *ERG* overexpression in response to androgens. Thus, antiandrogen therapy contributes to *ERG* downregulation in patients carrying *TMPRSS2-ERG* by decreasing androgen levels. In contrast, when the same patients evolve into a castration-resistant disease, fusion oncogene *TMPRSS2-ERG* overcomes AR regulation thus contributing to tumor progression.¹¹

Recently, we conceived siRNA to knockdown *TMPRSS2-ERG* expression but those short fragments of nucleic acids were rapidly metabolized into the blood stream and had poor intracellular diffusion.^{12,13} Therefore, the "squalenoylation" approach has been used. It is based on the covalent binding of the squalene (SQ), a natural and biocompatible lipid, to siRNA in order to protect siRNA *TMPRSS2-ERG* from rapid degradation.¹⁴ We showed that

¹Vectorology and Anticancer Therapies, UMR 8203, CNRS, Univ. Paris-Sud, Gustave Roussy, Université Paris-Saclay, Villejuif, France; ²INSERM UMR-S1147, 45 rue des Saints Pères, Paris, France; ³University College of Veterinary and Animal Sciences, Bahawalpur, Pakistan; ⁴Institut Galien, UMR 8612 CNRS, Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France. Correspondence: Liliane Massaad-Massade, Vectorology and Anticancer Therapies, UMR 8203, CNRS, Univ. Paris-Sud, Gustave Roussy, Université Paris-Saclay, Villejuif, France. E-mail: liliane.massade@gustaveroussy.fr

Received 15 December 2015; accepted 8 February 2016; published online 29 March 2016. doi:10.1038/mtna.2016.16

the resulting bioconjugate was able to self-assemble as nanoparticles (NPs) and inhibit PCa growth in mice bearing VCaP xenografted tumors. Moreover, the tumor growth inhibition was tightly correlated with a decrease in the oncoprotein expression and with a partially restored differentiation.¹⁵

Now, with the aim to elucidate if combining *TMPRSS2-ERG* suppression with impairment of AR signaling might have positive outcomes, or if the knockdown of fusion oncogene may represent an alternative strategy to hormone therapy, we combined siRNA *TMPRSS2-ERG* with FLU. We postulated that, in case of a synergistic enhancement of drug efficacy, FLU doses could be decreased substantially, thus allowing to hinder side effects. Similarly to other studies investigating associations between small molecules and oligonucleotides, FLU was used in this study at the concentration able to inhibit only 25% (IC_{25}) of PCa cell growth.^{16,17}

In parallel with the understanding of the possible benefits obtained from the combination of FLU with siRNA *TMPRSS2-ERG*, we also monitored in xenografted PCa, the transcriptional modifications of the main drug-metabolizing enzyme systems (MDMES) by each molecule alone or by the combination. The studied MDMES are phase 1 and 2 enzymes involved in drug functionalization and conjugation, respectively. FLU has been described to be metabolized mainly by cytochromes P450 (CYP) 1A2 and to a lesser extent by CYP 3A4 (refs. 6,18). In contrast, very little is known in literature about the modifications of CYP and phase 2 MDMES such as glutathione S-transferases (GST), uridine-5'-diphosphate glucuronosyltransferases (UGT), N-acetyltransferase (NAT), and sulfotransferase (ST) induced by the siRNAs and/or their vehicles when combined with other drugs. Therefore, transcriptional changes of MDMES should be more deeply investigated since there might be a tight correlation between these variations and the efficacy and/or toxicity of siRNA combinations with other drugs.

In this report, we confirm the therapeutic interest of nanomedicine based on siRNA *TMPRSS2-ERG* as an alternative to FLU.

Results

Optimization of androgens and antiandrogens on *TMPRSS2-ERG* gene expression and on VCaP cells viability

VCaP cell line was used in this study since it is described to be (i) hormone-dependent, (ii) tumorigenic in immunodeficient mice, and (iii) harboring *TMPRSS2-ERG* fusion oncogene which is regulated by androgens.¹⁹

First, we explored the physiological concentration of dihydrotestosterone (DHT) able to stimulate mRNA levels of *TMPRSS2-ERG* and *TMPRSS2* wild type by designing two primers, one covering *TMPRSS2-ERG* and the other outside the junction sequence. According to the literature, it should be approximately close to 10 nmol/l and the optimal incubation time of 24 hours.^{11,20,21} Therefore, VCaP cells were stimulated with 5, 10, and 50 nmol/l DHT, and the relative mRNA level of *TMPRSS2-ERG* was assessed. As shown in **Figure 1a**, a statistical increase of about 10-fold in *TMPRSS2-ERG* expression was observed in cells treated with 10 and 50 nmol/l of DHT. When the *TMPRSS2* gene was

investigated by using a specific primer amplifying the region not involved in the fusion, a more pronounced increase in mRNA levels of about 25-folds was observed when compared to untreated cells (**Figure 1b**). In both a and b panels, the maximal induction was obtained when VCaP cells were stimulated with 10 nmol/l of DHT. Beyond that, a plateau was reached when the concentration was further increased (50 nmol/l) (**Figure 1a,b**). Therefore, according to these data and previously published observations,¹¹ kinetics studies were performed at stimulating VCaP cells with 10 nmol/l of DHT.

At this optimal concentration, kinetics studies showed a statistical decrease for both mRNA levels (*TMPRSS2-ERG* and *TMPRSS2*) when cells were incubated for more than 24 hours (48 and 72 hours) (**Figures 1c,d**). These results are also in accordance with previously published studies showing that the optimal DHT stimulation is found at 24 hours.^{11,20,21}

Then, we studied the effect of FLU by MTT test and found that cell viability was affected in a dose-dependent manner (**Figure 1e**). The calculated IC_{50} and IC_{25} of FLU were 121 ± 3 and 64 ± 11 μ mol/l, respectively, and the latter was used in further studies to investigate the association between FLU and siRNA *TMPRSS2-ERG*. Thus, kinetic studies were performed to investigate *TMPRSS2-ERG* gene expression in presence of 70 μ mol/l FLU. **Figure 1f** depicted a drastic reduction in *TMPRSS2-ERG* mRNA expression when VCaP cells were treated with the antiandrogen only for 48 hours that slightly increased later or reached a plateau at 72 hours. Therefore, for further studies, DHT was applied at 10 nmol/l, 24 hours before treatment with: (i) FLU (70 μ mol/l for at least 48 hours) or (ii) siRNA *TMPRSS2-ERG* (50 nmol/l for at least 48 hours) as previously described,¹⁵ or the combined treatments of FLU (70 μ mol/l) plus siRNA *TMPRSS2-ERG* (50 nmol/l) for 48 hours.

Combination of siRNA *TMPRSS2-ERG* and FLU inhibits fusion oncogene and oncoprotein as much as the siRNA *TMPRSS2-ERG* alone

To understand which administration schedule would be the most appropriate to extensively inhibit the *TMPRSS2-ERG* fusion products, several combinations of siRNA *TMPRSS2-ERG* with FLU were tested (**Figure 2**). As previously shown in **Figure 1f**, shorter incubations (24 hours) are not sufficient to observe any inhibitory activity of FLU on the fusion products, hence longer incubations were tested. The cells were transfected with siRNA *TMPRSS2-ERG*: (i) before treatment with FLU (**Figure 2a**), (ii) 24 hours after the FLU was added (**Figure 2b**), or (iii) concomitantly with FLU (**Figure 2c**). As previously observed,¹⁵ siRNA *TMPRSS2-ERG* alone statistically decreased oncogene and oncoprotein expression of about 60–80% if cells were transfected before (**Figure 2a**, bar 4), after (**Figure 2b**, bar 4), or concomitantly with FLU administration (**Figure 2c**, bar 4). The siRNA control slightly increased, however not significantly, the *TMPRSS2-ERG* mRNA level that was not reflected on the protein content (**Figure 2a–c**, bar 2). Except for condition a, FLU alone (**Figure 2b,c**, bar 6) or combined with the siRNA control (**Figure 2a–c**, bar 3) was also able to decrease *TMPRSS2-ERG* expression, however, to a lower extent than the siRNA *TMPRSS2-ERG* alone. Concerning administration schedule a, the combination of siRNA *TMPRSS2-ERG* to FLU showed the highest decrease in *TMPRSS2-ERG* mRNA expression




Figure 1 Optimization of DHT and FLU concentrations and kinetics studies. (a and b) VCaP cells were stimulated with DHT at 5, 10, and 50 nmol/l for 24 hours. Cells were then harvested, mRNA collected, and RT-qPCR were performed to determine the relative mRNA levels of (a) TMPRSS2-ERG and (b) TMPRSS2 wild type. A significant difference was found between untreated and DHT-treated cells at 10 and 50 nmol/l. VCaP cells were incubated at 10 nmol/l DHT for 24, 48, or 72 hours and mRNA levels of (c) TMPRSS2-ERG and (d) TMPRSS2 wild type were determined. A statistical increase of mRNA levels was observed at 24 hours of stimulation compared to untreated cells. (e) The MTT viability assay was used to determine the IC_{50} and IC_{25} of FLU on VCaP cell line. First cells were incubated with DHT (10 nmol/l) for 24 hours, then different concentrations of FLU ($50 < \mu\text{mol/l} < 250$) were administered, and cells were incubated for 48 hours. Linear regression of plots calculated $\text{IC}_{50} \sim 120 \mu\text{mol/l}$ and $\text{IC}_{25} \sim 70 \mu\text{mol/l}$. (f) VCaP cells were stimulated with DHT (10 nmol/l) for 24 hours then incubated with 70 $\mu\text{mol/l}$ of FLU for 24, 48, and 72 hours. After RT-qPCR, a statistical difference was found between cells treated for 48 and 72 hours with FLU compared to untreated cells. The nonparametric Kruskal–Wallis statistical analysis followed by comparative Dunn's tests were performed using GraphPad software. * $P < 0.05$, ** $P < 0.01$. Bars represent at least two independent experiments performed in duplicates \pm SD. DHT, dihydrotestosterone; FLU, flutamide.

but is not reflected on protein content since ERG translation is already strikingly suppressed by siRNA TMPRSS2-ERG or FLU alone (Figure 2a). For the b and c tested administration schedules, when the siRNA TMPRSS2-ERG was combined to FLU, the mRNA level of TMPRSS2-ERG was similar to the cells receiving the siRNA TMPRSS2-ERG alone (Figure 2b,c, bars 4 and 5). Herein, protein content reflected mRNA behavior (Figure 2b,c).

Combination of siRNA TMPRSS2-ERG and FLU did not increase VCaP cell viability impairment

In most cases, an impairment of cell viability was observed for all the treatments (siRNA TMPRSS2-ERG (bar 4), FLU (bar 6), or combined molecules (bars 3 and 5)) and this, at all-time administration schedules compared to controls (vehicle (bar 1) and to siRNA control alone (bar 2)) (Figure 3). Worth of notice, no statistical difference was observed between combined treatments (bar 5) and each molecule alone (bars 4 and 6) unless when siRNA TMPRSS2-ERG was administered after FLU (Figure 3b, bar 4). As expected, the siRNA control (bar 2) did not affect VCaP cell viability unless if

combined with FLU (bar 3) whose effect is comparable with the treatment of the drug alone (bar 6).

Physicochemical properties of siRNA-SQ NPs

To preserve properties and efficacy of siRNA *in vivo*, both siRNA TMPRSS2-ERG and its corresponding siRNA control were covalently bound to the squalene to form an amphiphilic bioconjugate able to self-assemble as NPs in aqueous solutions.¹⁴ The synthesis of the bioconjugate was monitored by reverse-phase high-performance liquid chromatography. The increase in the lipophilic character of the siRNA when linked with squalene was indicated by the appearance of a retarded peak in the chromatogram testifying the formation of the siRNA-SQ conjugate. After hybridization of the bioconjugates (siRNA TMPRSS2-ERG-SQ and siRNA control-SQ) with the corresponding antisense strand and nanoprecipitation in water, the resulting NPs were monitored by laser light scattering analysis. The depicted size was of $\sim 250 \pm 50$ nm (five independent measurements). As explained in our previous study, the NPs siRNA TMPRSS2-ERG-SQ are not internalized *in vitro* and were only efficient in preclinical studies.¹⁵




Figure 2 Effects of combined siRNA TMPRSS2-ERG and FLU on fusion expression. VCaP cells (8×10^5 cells/well in a 6-well plate) were stimulated with DHT (10 nmol/l) 24 hours before treatments. Twenty-four hours later, (a) cells were transfected either with siRNAs TMPRSS2-ERG or siRNA control at 50 nmol/l and, 24 hours later, FLU (70 μ mol/l) was administered. Cells were then incubated for 48 hours. (b) FLU (70 μ mol/l) was administered, and cells were successively transfected 24 hours later with either siRNAs TMPRSS2-ERG or siRNA control at 50 nmol/l. Cells were then incubated for 48 hours. (c) Cells were transfected either with siRNAs TMPRSS2-ERG or siRNA control at 50 nmol/l, and FLU (70 μ mol/l) was administered at the same time. Cells were then incubated for 72 hours. For all conditions, cells were harvested then RNA and proteins were collected. Concerning mRNA levels, a statistical difference was observed between controls (untreated cells and siRNA control) and all treatments for a and c conditions, whereas only the siRNA TMPRSS2-ERG alone or combined with FLU showed a significance for condition b. For statistical analysis, the nonparametric Kruskal–Wallis followed by comparative Dunn’s tests were performed using GraphPad software. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. Bars represent the mean \pm SD of three independent experiments in duplicates. ERG protein was detected for each condition (a, b, and c) by western blot analysis. GAPDH was used as internal control. Western blot findings are consistent with mRNA behaviors toward treatments. DHT, dihydrotestosterone, FLU, flutamide.

Combined siRNA TMPRSS2-ERG-SQ NPs with FLU inhibits tumor growth *in vivo* similarly to siRNA TMPRSS2-ERG-SQ NPs alone

The treatment administration schedule in mice was based on the *in vitro* results wherein, the greatest inhibition of TMPRSS2-ERG fusion oncogene products and cell viability were obtained when the siRNA TMPRSS2-ERG was transfected with lipofectamine. This was observed when cells were transfected with siRNA TMPRSS2-ERG and then treated with FLU for 48 hours (condition a in previous experiments). As mentioned in the Material and Methods section, combined or single treatments were administered to SCID mice over 5 weeks at cumulative doses of 0.8 mg/kg for squalenoylated siRNA NPs and of 11.2 mg/kg for FLU. As shown in Figure 4a, when siRNA TMPRSS2-ERG-SQ NPs alone or combined with FLU were injected, tumor growth was strikingly inhibited compared to mice treated with saline solution

(decrease of tumor growth of about 50%, $P < 0.01$) or siRNA control-SQ NPs (decrease of tumor growth of about 60%, $P < 0.001$). When mice were treated with FLU alone or combined to the siRNA control, only a slight inhibition of tumor growth of about 20% was noticed that not reached significant difference comparatively to control treatments (NaCl, siRNA control-SQ NPs). The growth curve corresponding to antiandrogen-treated mice showed intermediate growth inhibition behavior between the control and treated mice groups explaining the absence of significance.

Tumors collected at the end of the experiment were analyzed by western blot for the expression of ERG oncoprotein, AR, and cleaved caspase-3. ERG protein expression was inhibited within the tumors treated with siRNA TMPRSS2-ERG-SQ NPs alone or combined with FLU (Figure 4b, lines 4 and 5, respectively). The expression of AR was downregulated when tumors were treated with FLU




Figure 3 Effects of combined siRNA TMPRSS2-ERG and FLU on cell viability. VCaP cells were stimulated with DHT (10 nmol/l) 24 hours before treatments. The next day, (a) cells were transfected either with siRNAs TMPRSS2-ERG or control at 50 nmol/l, and 24 hours later, FLU (70 μ mol/l) was added. Cells were then incubated for 48 hours. (b) FLU (70 μ mol/l) was administered, and cells were successively transfected 24 hours later with either siRNAs TMPRSS2-ERG or control at 50 nmol/l. Cells were then incubated for 48 hours. (c) Cells were transfected either with siRNAs TMPRSS2-ERG or control at 50 nmol/l, and FLU (70 μ mol/l) was administered concomitantly. MTT viability test was performed, 100% cell viability corresponds to the number of living cells incubated with vehicle. Results are the mean \pm SD of two independent experiments containing eight replicates for each condition. The nonparametric Kruskal–Wallis followed by comparative Dunn's tests were performed for statistical analysis. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. DHT, dihydrotestosterone; FLU, flutamide.

alone (line 6) but to lower or no extent when FLU was combined to siRNA (TMPRSS2-ERG or control)-SQ NPs (lines 5 and 3, respectively). Moreover, in tumors treated with siRNA TMPRSS2-ERG SQ NPs alone (line 4) or combined with FLU (line 5), a slight increase in expression of cleaved caspase-3 was clearly observed suggesting an increase of apoptotic cells within the tumors, which was not observable after the other treatments (saline solution treated tumors or siRNA control-SQ NPs with or without FLU or FLU alone).

Combined treatments mostly inhibit cytochrome P450 enzymes induction by flutamide

First, we screened the expression profile of 34 CYP mRNAs isoforms of CYP1, CYP2, CYP3, CYP4, and CYP46 in untreated xenografted tumors. The sequence of TATA box binding protein was used as internal control. The cycle threshold of 30 was imposed in order to obtain reliable results from real-time PCR (Figure 5a).

Among the 34 CYP isoforms studied, only CYP2 and CYP4 families were found to be expressed within the tumors and

more precisely the following isoforms: CYP2D6, CYP2J2, CYP2R1, CYP2U1, CYP2W1, CYP4F8, CYP4F12, and CYP4F22. The CYP1A2 described to be responsible of FLU metabolism¹⁸ was not found in our VCaP xenografted tumors.

Then, we studied the expression of the isoforms after treatments and found a significant difference in the mRNA expression of five isoforms: CYP2D6, CYP2R1, CYP4F8, CYP4F12, and CYP4F22 (Figure 5b–f). This significance is mainly due to FLU treatment (bars 6) except for CYP2D6 (Figure 5b), however, for this isoenzyme, an mRNA inhibition of 50% was observed when the tumors were treated with siRNA TMPRSS2-ERG-SQ NPs alone or combined with FLU (bars 4 and 5, respectively). The inhibition was significant and specific of targeted siRNA TMPRSS2-ERG-SQ NPs, while that of siRNA control-SQ NPs (bars 2) was not different from the other treated groups. CYP2R1 expression was significantly increased by FLU alone (Figure 5c, bar 6) compared to saline solution or siRNA control-SQ NPs treated tumors (bars 1 and 2, respectively); however, none of the other treatments seems to modify the expression of this isoform.




Figure 4 Combined siRNA TMPRSS2-ERG-SQ NPs with FLU inhibits tumor growth *in vivo* similarly to siRNA TMPRSS2-ERG-SQ NPs.

(a) SCID mice bearing VCaP tumor xenografts were injected i.v. either with saline solution (1), siRNA control-SQ NPs alone (2) or combined with FLU (3), NPs siRNA TMPRSS2-ERG-SQ alone (4) or combined with FLU (5), or FLU alone (6). Mice receiving combined treatments were injected alternatively with siRNA-SQ NPs or FLU every 48 hours and for 5 weeks as explained in the pictogram. The tumor growth of 10 tumors per condition was followed during the course of the experiment. Using Kruskal–Wallis followed by comparative Dunn's tests, a statistical difference was observed between controls (mice treated with saline solution or siRNA control-SQ NPs) and siRNA TMPRSS2-ERG-SQ NPs alone or combined with FLU ($***P < 0.001$, $**P < 0.01$). Data are the mean \pm SEM of 10 independent tumors. (b) Mice were sacrificed, and tumors were collected at the end of the experiment and ERG, AR, and cleaved caspase-3 protein expressions were analyzed by western blot. GAPDH was monitored as loading control. FLU, flutamide; NP, nanoparticles; SQ, squalene.

A similar behavior was observed, with more striking results when family 4 of CYP was observed (Figure 5d–f). Indeed, FLU alone was able to induce from 5- to 500-fold in the expression of CYP4F8 (Figure 5d), 4F12 (Figure 5e), 4F22 (Figure 5f), though this effect was completely reversed or reduced when the drug was associated with siRNAs-SQ NPs (TMPRSS2-ERG or control).

Combined treatments respond differently to induce the main phase II drug metabolizing enzymes by flutamide

The enzymes mainly involved in phase 2 of drugs metabolism (conjugation enzymes, including several transferases) and epoxide hydrolase (EH) were also investigated. As previously mentioned, the cycle threshold (Ct) of 30 was imposed in order to obtain reliable results from qPCR. GST α , μ or π isoforms, EH and UGT1A1 were found to be expressed within the tumors (Ct < 30); NAT1 was expressed at the limit of 30 Ct in saline solution treated mice; however, it reached higher expression for all other treatments; thus, it was included in the study. The ST showed a signal beyond 30 Ct for all the treated tumors; thus, no relative quantification ($\Delta\Delta Ct$) was calculated for this enzyme (Figure 6a).

GST α and EH did not show significant modification by any treatment. NAT1, UGT1A1, GST π 1, and GST μ 1 showed the same profile (Figure 6b–e). A significant upregulation of phase 2 drug-metabolizing enzymes mRNA was observed when mice were treated with siRNA control-SQ NPs combined with FLU (bar 3), siRNA TMPRSS2-ERG-SQ NPs (bar 4), and FLU alone (bar 6). However, the siRNA TMPRSS2-ERG-SQ NPs combined with FLU (bars 5)

showed the same profile as that of mice treated with saline solution (bars 1) or with the siRNA control-SQ NPs alone (bars 2), suggesting that combined treatments responded differently to the induction by FLU.

Discussion

In this study, we investigated the therapeutic effects of combining AR inhibition by the antiandrogen FLU, one of the reference treatment for PCa, with the *TMPRSS2-ERG* knockdown by siRNA. This fusion oncogene is described to disrupt AR signaling pathway, thus promoting the growth of prostate cancer cells.²² Moreover, *TMPRSS2-ERG* expression is preserved in castration-resistant form compared to other AR target genes which are generally downregulated,¹¹ supporting the interest in targeting the fusion oncogene as an alternative therapeutic strategy to androgen deprivation therapy or in combining both treatments. Indeed, drug associations are generally meant to diminish drug doses, thus toxicity or to counteract cancer development via multiple pathways. TMPRSS2 presents several androgen-responsive elements in its promoter, thus explaining the efficacy of the antiandrogen on downregulating the *TMPRSS2-ERG* expression. Herein, this study intended to decrease FLU toxicity by combining this molecule at lower doses to siRNA against TMPRSS2-ERG.

Because the inhibition at the posttranscriptional level carried out by the siRNA might differ from the disruption of AR signaling by FLU in terms of kinetics, three different administration protocols were adopted to understand which




Figure 5 Combined treatments mostly inhibit cytochrome P450 enzymes induction by FLU. (a) Tumors were grinded, and RNA was collected. RT-qPCR was performed, and cDNA was amplified by RT-qPCR for cytochromes P450. The threshold of 30 cycles was imposed in order to obtain reliable results from RT-PCR. Relative mRNA expressions of (b) CYP 2D6, (c) 2R1, (d) 4F8, (e) 4F12, and (f) 4F22 were recorded as fold change normalized to saline solution treated tumors. *TATA Box Binding Protein* (TBP) gene was used as reference gene. For statistical analysis, the nonparametric Kruskal–Wallis followed by comparative Dunn's tests were performed using GraphPad software. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. Bars represent the mean \pm SD of three independent tumors and three independent replicates. FLU, flutamide; CYP, cytochrome P450.

one would be the most appropriate. We observed that the combination of the two molecules cannot display a more pronounced TMPRSS2-ERG inhibitory effect compared to the oligonucleotide alone whatever the treatment schedule applied. This can be explained by the fact that the siRNA TMPRSS2-ERG is already able to downregulate extensively TMPRSS2-ERG mRNA and its corresponding ERG protein expression without the need of inhibitory enhancers such as FLU. This observation was confirmed by cell mortality studies where the combination of the two drugs did not impair the cell viability better than each molecule alone. Moreover, similar results were observed when the siRNA TMPRSS2-ERG was combined to 120 $\mu\text{mol/l}$ of FLU (corresponding to the IC_{50} , data not shown). This suggests

that the absence of synergism or additivity was not due to FLU concentration.

Since the drug metabolism *in vivo* might affect the outcome of the combination treatment and differs substantially from *in vitro* studies, the combinatorial treatment was tested in mice bearing VCaP xenografted tumors. However, to preserve siRNA efficacy *in vivo*, the oligonucleotide must be protected from nuclease degradation and effectively delivered into the tumors.²³ Consequently, squalenoylated siRNA NPs were formulated with this intent.¹⁴

As previously described and discussed in our latest paper,¹⁵ *in vitro*, the NPs siRNA TMPRSS2-ERG-SQ were unable to enter within the cells without a transfecting agent. But we already demonstrated that they are still active




Figure 6 Combined treatments respond differently to the induction of the main phase 2 drug-metabolizing enzymes by FLU. (a) Tumors were grinded, and RNA was collected. Reverse transcription was performed and cDNA was amplified by RT-PCR for phase 2 enzymes. The threshold of 30 cycles was imposed in order to obtain reliable results from RT-PCR. Relative mRNA expressions of (b) NAT1, (c) UGT1A1, (d) GSTπ1, and (e) GSTμ1 were recorded as fold change normalized to saline solution treated tumors. *TATA Box Binding Protein* (TBP) gene was used as reference gene. For statistical analysis, the nonparametric Kruskal–Wallis followed by comparative Dunn's tests were performed using GraphPad software. * $P < 0.05$; ** $P < 0.01$, *** $P < 0.001$. Bars represent the mean \pm SD of three independent tumors and three independent replicates. FLU, flutamide; NP, nanoparticles; SQ, squalene.

after bio-conjugation with squalene despite the chemical modifications.^{14,15,24,25}

In vivo, we found comparable results between siRNA TMPRSS2-ERG-SQ NPs administered alone or combined to FLU. In contrast, FLU alone showed similar tumor growth profile compared to control-treated mice. Hence, the *TMPRSS2-ERG* expression profile reflected tumor response to treatments. Regarding AR expression, its decrease by FLU was not correlated with tumor growth inhibition, and this effect was slightly counteracted when combined with siRNA TMPRSS2-ERG-SQ NPs. This result is in accordance with the role of ERG overexpression in inhibiting AR expression,

thus *TMPRSS2-ERG* knockdown may partially restore AR expression.²⁶ Moreover, a slight increase in the apoptotic status of tumors via the cleavage of caspase 3 was only observable in mice treated with siRNA TMPRSS2-ERG-SQ NPs alone or combined with FLU which is in accordance with the tumor growth inhibition shown essentially by these two treatments. To understand the mechanisms underlying these observations, we studied the main drug-metabolizing systems by assessing phase 1 (CYP, EH) and phase 2 (conjugation enzymes, including several transferases) enzymes. To our knowledge, the expression of these enzymes has not been investigated so far under the treatment of squalene-based

NPs. We observed that both phase 1 and phase 2 enzymes seems not to play a key role in metabolism of NPs. On the contrary, FLU extensively modified the expression of these enzymes. Nevertheless, the induction observed for these enzymes by the antiandrogen was counteracted by its association with squalenoylated siRNA NPs for phase 1 enzymes and with siRNA control-squalene NPs for phase 2 enzymes. This observation is in accordance with Kocarek et al.²⁷, who observed a strong increase of CYP2B and 4A mRNA levels in primary cultured rat hepatocytes when treated with squalastatin 1, a potent inhibitor of squalene synthase. Thus, the inhibition of families 2 and 4 of CYP by squalene might influence the FLU activity by decreasing its metabolism rate. However, upregulation of phase 2 enzymes by FLU alone or combined with siRNA control-SQ NPs could explain the observed decrease of antitumoral activity of the corresponding treated groups.

In addition, CYP4F8, an enzyme involved in the synthesis of prostaglandins which are responsible for the onset of inflammation has been described to be overexpressed in primary prostate cancer samples and its inhibition reduced cell viability in various PCa cell lines.²⁸ Moreover, ERG overexpression is described to inhibit the 15-hydroxy-prostaglandin dehydrogenase, an enzyme in charge of oxidation of prostaglandin into inactive keto-metabolites, thus the fusion oncogene participates to the inflammatory process of PCa.²⁹ These findings suggest that the administration of siRNA TMPRSS2-ERG squalene-based NPs could decrease inflammation generally related to cancer development by inhibiting transcription of CYPs involved in prostaglandins synthesis and by upregulating 15-hydroxy-prostaglandin dehydrogenase responsible of prostaglandins catabolism.

With regard to phase 2 enzymes, their behavior toward FLU is different when the combination occurs with the target or scrambled sequences; therefore, the role of the junction oncogene on the activities of the phase 2 enzymes should be more deeply investigated.

In conclusion, siRNA TMPRSS2-ERG-SQ NPs confirmed their strong antitumoral activity and could be considered as an alternative therapeutic approach for hormone-dependent prostate cancer. Moreover, the significance of siRNA-SQ NPs has been demonstrated in preclinical trials of thyroid and prostate cancers.^{14,15,24,25} Thus, further investigations should be proceeded to prove the safety of our vectors in term of toxicological test that will allow to progress into clinical trials. So that, the "squalenoylation" could be used as a generic platform for the administration and the transport of therapeutic siRNA.

Materials and methods

Chemicals. Squalene, siRNA, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) reagents were purchased from Sigma-Aldrich Chemical (Saint Quentin Fallavier, France). Single-strand siRNA was synthesized as 21-mer with two 2'-deoxynucleotide residues at the 3'-end to provide stabilization against nucleases.³⁰ For bioconjugation to squalene, siRNA was modified at the 3'-end with a thiol group (Eurogentec, Belgium).

Dulbecco's modified Eagle medium, Opti-MEM, fetal calf serums, Lipofectamine RNAiMAX, and PCR primers were purchased from Life Technologies (Saint Aubin, France). BD Matrigel (Basement Membrane Matrix Growth Factor Reduced - Reference 356234) was purchased from Corning (Amsterdam, the Netherlands). Bio-RAD protein assay was purchased from Bio-RAD Laboratories (Marnes-la-Coquette, France). All used chemicals were of quality grade.

Cell line and culture. Human prostate cancer VCaP cell line expressing *TMPRSS2-ERG* oncogene (CRL2876, ATCC, Manassas, VA) was grown in Dulbecco's modified Eagle medium supplemented with 10% of fetal calf serums, 100 units/ml penicillin, and 100 µg/ml streptomycin (Invitrogen, Cergy-Pontoise, France). Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO₂. Cells were regularly analyzed to ensure absence of contaminations by mycoplasma.

Influence of DHT on fusion transcription. To determine the DHT concentration able to induce the highest *TMPRSS2-ERG* expression, VCaP cells (8 × 10⁵ cells/well) were seeded in a six-well plate and treated with DHT at 5, 10, and 50 nmol/l concentrations for 24 hours. The concentration able to predominantly induce TMPRSS2-ERG fusion transcript was then used to incubate VCaP cells for 24, 48, and 72 hours in order to optimize the stimulation schedule. At the end of treatments, cells were collected, mRNA extracted, and reverse transcription-quantitative PCR (RT-qPCR) was performed to analyze *TMPRSS2-ERG* and *TMPRSS2* genes expressions.

Real-time PCR (RT-qPCR). Total RNA was extracted from VCaP cells by RNeasy mini-kit (Qiagen, Courtaboeuf, France) and first-strand cDNA was generated with M-MLV RT buffer kit (Life Technologies) as previously described.²⁴ The following primers were used to amplify *TMPRSS2-ERG* junction sequence: forward 5'-GGCAGGAACTCTCCTGAT-3', reverse 5'-CGTGGCACGATAACTCTG-3'. The *TMPRSS2* gene was also investigated by using specific primers amplifying the region not involved within the fusion: *TMPRSS2* forward 5'-AAGGGAAGACCTCAGAAGTG-3', reverse 5'-CCAGTCCGTGAATACCATC-3'. GAPDH sequence was used as housekeeping gene: forward 5'-CCACTCCTCCACCTTTGAC-3', reverse 5'-ACCCTGTTGCTGTAGCCA-3'. RT-qPCR was performed using the StepOne-Plus PCR System (AB Applied Biosystems, Villebon-sur-Yvette, France) using GoTaq qPCR Master Mix (Promega, Charbonnières-les-Bains, France) according to manufacturer's instructions. Samples were run in triplicate; gene regulation was determined by 2^{-ΔΔCt} method and normalized to GAPDH levels. Results are given as relative mRNA levels of *TMPRSS2-ERG* or of *TMPRSS2* compared to nontreated cells.

Determination of the inhibitory concentrations (IC₅₀ and IC₂₅) of flutamide on viability of VCaP cells. The FLU dose-response curve was assessed on VCaP cells to determine the concentration of the drug to be used in association with siRNA TMPRSS2-ERG. Cells were plated into a 96-well plate (30,000 cells/well), and simultaneously treated with DHT (10 nmol/l) for 24 hours. FLU was then added to various

micromolar concentrations (50, 100, 150, 200, and 250 $\mu\text{mol/l}$), and cells were incubated for 48 hours. The viability of VCaP cells was evaluated by MTT assay. The concentrations of FLU required to affect 25% (IC_{25}) and 50% (IC_{50}) of cell viability were determined by linear regression model.

Influence of flutamide on fusion transcription. VCaP cells (8×10^5 cells/well) were seeded in six-well plates and stimulated with DHT (10 nmol/l). Twenty-four hours later, cells were stimulated with FLU (70 $\mu\text{mol/l}$) for 48 hours. At the end of the treatment, cells were harvested and total mRNA was extracted to be analyzed for *TMPRSS2-ERG* and *TMPRSS2* expression by RT-qPCR as described above.

In vitro cell transfection. Transient transfections were performed to assess the most efficient drug combination protocol of siRNA *TMPRSS2-ERG* and FLU for oncofusion knockdown. Cells were transfected with siRNA against *TMPRSS2-ERG* using Lipofectamine RNAiMAX transfecting agent and according to manufacturer's instructions. One siRNA containing four mismatches on the sequence of the siRNA *TMPRSS2-ERG* was used as siRNA control.

First, VCaP cells (8×10^5) were seeded in six-well plates and stimulated with DHT (10 nmol/l). Twenty-four hours later, three different administration schedules were applied: (i) cells were transfected with siRNA *TMPRSS2-ERG* (50 nmol/l) for 24 hours, then stimulated with FLU (70 $\mu\text{mol/l}$) for 48 hours; (ii) cells were stimulated with FLU (70 $\mu\text{mol/l}$) for 24 hours, then transfected with siRNA *TMPRSS2-ERG* (50 nmol/l) for 48 hours; (iii) cells were transfected with siRNA *TMPRSS2-ERG* (50 nmol/l) and stimulated with FLU (70 $\mu\text{mol/l}$) at the same time, then incubated for 48 hours. At the end of the treatments, mRNA and proteins were extracted and analyzed for gene and protein expressions.

Immunoblotting. Total protein extracts were obtained using M-PER reagent (Thermo Fisher Scientific, Courtaboeuf, France) supplemented with a protease inhibitor cocktail (Roche, Neuilly sur Seine, France) as previously described.²⁴ Proteins were titrated by Bio-RAD Assay according to manufacturer's instructions. Samples were then loaded on 10% polyacrylamide gel (NuPAGE Bis Tris Mini Gels 10%, Life Technologies, Saint-Aubin, France) and proteins were transferred using the iBlotDry Blotting System (Invitrogen). Membranes were incubated overnight at 4 °C with monoclonal rabbit anti-ERG (EPR 3864 (2); 1:500, Abcam Biochemicals, Paris, France). Monoclonal mouse GAPDH-horseradish peroxidase (#3683; 1:1000, Cell Signaling technology, Saint Quentin en Yvelines, France) was used as internal control. Blots were then washed and, when necessary, incubated with corresponding secondary antirabbit antibodies conjugated to horseradish peroxidase (1:3,000; Cell Signaling Technology). Bands were visualized by enhanced chemiluminescence reagent (Invitrogen).

Viability assay. The MTT assay was performed to determine the most efficient drug combination protocol for cell viability impairment, as previously described.²⁵

First, VCaP cells (3×10^4) were seeded in 96-well plates and stimulated with DHT (10 nmol/l). Twenty-four hours later,

three different administration schedules were applied: (i) cells were transfected with siRNA (*TMPRSS2-ERG* or control at 50 nmol/l) for 24 hours, then stimulated with FLU (70 $\mu\text{mol/l}$) for 48 or 72 hours; (ii) cells were stimulated with FLU (70 $\mu\text{mol/l}$) for 24 hours, then transfected with siRNA (*TMPRSS2-ERG* or control at 50 nmol/l) for 48 or 72 hours; (iii) cells were transfected with siRNA (*TMPRSS2-ERG* or control at 50 nmol/l) and stimulated simultaneously with FLU (70 $\mu\text{mol/l}$) then incubated for 48 or 72 hours. At the end of treatments, MTT reagent (20 μl of 5 mg/ml phosphate-buffered saline) was added to each well and incubated at 37 °C for 2 hours. Results are the mean \pm SD of two independent experiments containing eight replicates for each condition and are expressed as cell viability percentage of treated cells compared to nontreated cells.

Preparation of siRNA *TMPRSS2-ERG-squalene* NPs. In order to perform squalene bio-conjugation, a 3-mercaptopropyl phosphate group was introduced at the 3'-end of siRNA sense strand (synthesized by Eurogentec, Belgium).

The bioconjugate siRNA *TMPRSS2-ERG-SQ* was synthesized by Michael addition of 3'-thiol group with squalene-(ethoxy)ethyl-maleimide, and the corresponding NPs were prepared by nanoprecipitation as previously published.¹⁴ The hydrodynamic diameter (nm) was measured by laser light scattering using a Zetasizer 4 (Malvern Instrument, Orsay, France).

Table 1 Primers of the main phase 1 and phase 2 drug-metabolizing enzymes^a

CYPs:	Patented sequences kindly provided by:
1A1, 1A2, 1B1	
2A6, 2A7, 2A13, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 2F1, 2J2, 2R1, 2S1, 2U1, 2W1	Dr I. de Waziers, UMR S-1147, Paris Descartes ³²
3A4, 3A5, 3A7	
4A11, 4A22, 4B1, 4F2, 4F3, 4F8, 4F11, 4F12, 4F22, 4X1, 4Z1	
46A1	
Epoxide hydrolase F	5' GAC AAC AGG CAC CAT CAT C 3'
Epoxide hydrolase R	5' AAA AGG GAA GGC AGA GAA G 3'
Glutathione S transferase α 1 F	5' GAG ATT GAT GGG ATG AAG C 3'
Glutathione S transferase α 1 R	5' CAA AGG CAG GGA AGT AGC 3'
Glutathione S transferase μ 1 F	5' CTG TCT GGG GCA ACA AGT AG 3'
Glutathione S transferase μ 1 R	5' GGT TTA GGG GGA GTG AAG AG 3'
Glutathione S transferase π 1 F	5' GGC AAG ACC TTC ATT GTG 3'
Glutathione S transferase π 1 R	5' CCA ACC CTC ACT GTT TCC 3'
Aryl amine N-acetyltransferase 1 F	5' CTC CAG CCA AAA AAT ACA GC 3'
Aryl amine N-acetyltransferase 1 R	5' TCC ATT CTC TTC CGT CAA AC 3'
Sulfotransferase F	5' CCG CCA TCC TTT CAT TGA G 3'
Sulfotransferase R	5' CCC AAA CCA CTT TTC CAT TG 3'
UDP glucuronosyltransferase 1A1 F	5' TCT GGG TGG AGT TTG TGA TG 3'
UDP glucuronosyltransferase 1A1 R	5' ATG GGT CTT GGA TTT GTG G 3'

^aNucleotide primers pairs of CYP450 families were kindly provided by Dr I. de Waziers and are available from Biopredic International (Rennes, France, <http://www.biopredic.com>). Primers for phase 2 enzymes of metabolism were designed and validated and sequences are listed in the table.

Animal studies. *In vivo* studies were permitted and accepted by the research council (Integrated Research Cancer Institute in Villejuif, IRCIV), the institutional Ethics Committee of Animal Experimentation and registered in the French Ministry of Higher Education and Research. Authorization Committee of Animal Experimentation IRCIV/IGR (no. 26: 94–226, no: 2011-09) was applied, and all animal studies were carried out in accordance with the French laws and regulations and applying the European Community directives (Directive 2010/63/UE). Animal suffering was minimized through the use of isoflurane anesthesia when treatments were administered, and mice were sacrificed by CO₂ inhalation before tumor collection. Five-week-old SCID/Beige mice were obtained from Harlan Laboratory. Sterilized laminar flow caging system was used to house animals and food, water, and bedding were autoclaved before use. Food and water were provided *ad libitum*.

***In vivo* antitumoral activity of combined siRNA TMPRSS2-ERG-SQ NPs and flutamide.** VCaP cells were *sc* inoculated (10⁷ cells/mouse in PBS (50 µl) mixed with Matrigel (50 µl)). When tumors reached about 50 mm³, mice (*n* = 10 tumors/group) were treated by i.v. injection of 0.9% NaCl or squalenoylated siRNA and/or by i.p. injection of FLU. The administration schedule was carried out over 5 weeks. The following treatments were administered: (i) every 48 hours, 100 µl of NaCl 0.9%; (ii) every 96 hours squalenoylated siRNA (siRNA TMPRSS2-ERG-SQ NPs or siRNA control) NPs at the cumulative dose of 0.8 mg/kg (eight injections of 0.1 mg/kg/injection dispersed in 100 µl of 0.9% NaCl solution); (iii) every 96 hours, FLU alone at cumulative dose of 11.2 mg/kg (seven injections of 1.6 mg/kg/injection dispersed in sterilized sesame oil). For combination studies, treatments were alternated beginning with siRNA TMPRSS2-ERG-SQ NPs (or siRNA control) NPs and followed 48 hours later by FLU. The combined treatments were performed at the same doses of drugs administered. Mice were monitored daily and sacrificed at the end of the experiment unless signs of animal suffering (body weight loss, abnormal behavior, toxicity signs) were observed or, if tumors reached a volume of 1,000 mm³. After sacrifice of animals, tumors were collected and immediately frozen in liquid nitrogen for proteins and mRNA analysis.

Protein extractions from tumors. Total protein extraction using M-PER lysis buffer and western blot were performed for ERG, cleaved caspase-3 (# 9662; 1:1,000; Cell Signaling Technology) and GAPDH as described above. Knowing that FLU prevents nuclear shuttling of AR, nuclear protein extraction was achieved as described by Erin *et al.*³¹, then western blot were performed using AR antibody (ab108341; 1:1,000, Abcam Biochemicals).

Tumor expression of the main drug-metabolizing enzymes systems. For the determination of phase 1 (CYP and EH) and phase 2 (GSTs, UGT1, NAT1, EH, and ST) metabolizing enzymes, tumors were ground and total RNA was extracted by RNeasy minikit according to manufacturer's instructions. RT-qPCR was performed as described above for *in vitro* studies. Nucleotide primer pairs of CYP450 families

were designed and kindly provided by de Waziers.³² Primers for EH and phase 2 xenobiotic metabolizing enzymes were designed, their sequences are listed in Table 1. *TBP* gene (coding for the TATA box-binding protein, a component of the DNA-binding protein complex TFIID) was used as endogenous control.³³ Results are presented as relative mRNA level compared to 0.9% saline solution treatment.

Statistical analysis. All data are presented as mean ± SD. For statistical analysis, we used the nonparametric Kruskal–Wallis followed by Dunn's tests to identify the sources of differences among treatments by using GraphPad software. *P* ≤ 0.05 was considered as a statistically significant difference.

Acknowledgments The research leading to these results has received funding from: (i) the Agence Nationale de Recherche (ANR), Program P2N, Grant No: NANO 0030 and (ii) a public grant overseen by the French National Research Agency (ANR) as part of the “Investissements d’Avenir” program (Labex NanoSaclay, reference: ANR-10-LABX-0035). The animal studies were performed within the animal facility of the Gustave Roussy Cancer Campus, and the authors gratefully acknowledge the excellent technical support of their employees. The authors declare no conflict of interest.

- Cuzick, J, Thorat, MA, Andriole, G, Brawley, OW, Brown, PH, Culig, Z *et al.* (2014). Prevention and early detection of prostate cancer. *Lancet Oncol* 15: e484–e492.
- DeSantis, CE, Lin, CC, Mariotto, AB, Siegel, RL, Stein, KD, Kramer, JL *et al.* (2014). Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin* 64: 252–271.
- Akduman, B and Crawford, ED (2006). Treatment of localized prostate cancer. *Rev Urol* 8 (suppl. 2): S15–S21.
- Huggins, C and Hodges, CV (2002). Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. *J Urol* 168: 9–12.
- Labrie, F (1993). Mechanism of action and pure antiandrogenic properties of flutamide. *Cancer* 72 (suppl. 12): 3816–3827.
- Ricci, F, Buzzatti, G, Rubagotti, A and Boccardo, F (2014). Safety of antiandrogen therapy for treating prostate cancer. *Expert Opin Drug Saf* 13: 1483–1499.
- Shafi, AA, Yen, AE and Weigel, NL (2013). Androgen receptors in hormone-dependent and castration-resistant prostate cancer. *Pharmacol Ther* 140: 223–238.
- Tomlins, SA, Rhodes, DR, Perner, S, Dhanasekaran, SM, Mehra, R, Sun, XW *et al.* (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 310: 644–648.
- Attard, G, Swennenhuis, JF, Olmos, D, Reid, AH, Vickers, E, A'Hern, R *et al.* (2009). Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. *Cancer Res* 69: 2912–2918.
- Mehra, R, Tomlins, SA, Yu, J, Cao, X, Wang, L, Menon, A *et al.* (2008). Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. *Cancer Res* 68: 3584–3590.
- Cai, C, Wang, H, Xu, Y, Chen, S and Balk, SP (2009). Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. *Cancer Res* 69: 6027–6032.
- Christensen, J, Litherland, K, Faller, T, van de Kerkhof, E, Natt, F, Hunziker, J *et al.* (2013). Metabolism studies of unformulated internally [3H]-labeled short interfering RNAs in mice. *Drug Metab Dispos* 41: 1211–1219.
- Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W *et al.* (2005). Potent and persistent *in vivo* anti-HBV activity of chemically modified siRNAs. *Nat Biotechnol* 23: 1002–1007.
- Raouane, M, Desmaele, D, Gilbert-Sirieix, M, Gueutin, C, Zouhiri, F, Bourgaux, C *et al.* (2011). Synthesis, characterization, and *in vivo* delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. *J Med Chem* 54: 4067–4076.
- Urbini, G, Ali, HM, Rousseau, Q, Chapuis, H, Desmaële, D, Couvreur, P *et al.* (2015). Antineoplastic effects of siRNA against TMPRSS2-ERG junction oncogene in prostate cancer. *PLoS One* 10: e0125277.
- Lin, YL, Yuksel Durmaz, Y, Nör, JE and ElSayed, ME (2013). Synergistic combination of small molecule inhibitor and RNA interference against antiapoptotic Bcl-2 protein in head and neck cancer cells. *Mol Pharm* 10: 2730–2738.
- Rytelewski, M, Ferguson, PJ, Maleki Vareki, S, Figueredo, R, Vincent, M and Koropatnick, J (2013). Inhibition of BRCA2 and thymidylate synthase creates multidrug

- sensitive tumor cells via the induction of combined "complementary lethality". *Mol Ther Nucleic Acids* **2**: e78.
18. Shet, MS, McPhaul, M, Fisher, CW, Stallings, NR and Estabrook, RW (1997). Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. *Drug Metab Dispos* **25**: 1298–1303.
 19. Cai, J, Kandagatla, P, Singareddy, R, Kropinski, A, Sheng, S, Cher, ML *et al.* (2010). Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells. *Transl Oncol* **3**: 195–203.
 20. Wang, Q, Carroll, JS and Brown, M (2005). Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. *Mol Cell* **19**: 631–642.
 21. Wang, Q, Li, W, Liu, XS, Carroll, JS, Jänne, OA, Keeton, EK *et al.* (2007). A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. *Mol Cell* **27**: 380–392.
 22. Yu, J, Yu, J, Mani, RS, Cao, Q, Brenner, CJ, Cao, X *et al.* (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. *Cancer Cell* **17**: 443–454.
 23. Ali, HM, Urbinati, G, Raouane, M and Massaad-Massade, L (2012). Significance and applications of nanoparticles in siRNA delivery for cancer therapy. *Expert Rev Clin Pharmacol* **5**: 403–412.
 24. Ali, HM, Maksimenko, A, Urbinati, G, Chapuis, H, Raouane, M, Desmaële, D *et al.* (2014). Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol. *Thyroid* **24**: 327–338.
 25. Ali, HM, Urbinati, G, Chapuis, H, Desmaële, D, Bertrand, JR, Couvreur, P *et al.* (2014). Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations. *PLoS One* **9**: e95964.
 26. Chen, Y and Sawyers, CL (2010). Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. *Cancer Cell* **17**: 415–416.
 27. Kocarek, TA, Kraniak, JM and Reddy, AB (1998). Regulation of rat hepatic cytochrome P450 expression by sterol biosynthesis inhibition: inhibitors of squalene synthase are potent inducers of CYP2B expression in primary cultured rat hepatocytes and rat liver. *Mol Pharmacol* **54**: 474–484.
 28. Vainio, P, Gupta, S, Ketola, K, Mirtti, T, Mpindi, JP, Kohonen, P *et al.* (2011). Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. *Am J Pathol* **178**: 525–536.
 29. Mohamed, AA, Tan, SH, Sun, C, Shaheduzzaman, S, Hu, Y, Petrovics, G *et al.* (2011). ERG oncogene modulates prostaglandin signaling in prostate cancer cells. *Cancer Biol Ther* **11**: 410–417.
 30. Tuschl, T (2002). Expanding small RNA interference. *Nat Biotechnol* **20**: 446–448.
 31. Erin, N, Bronson, SK and Billingsley, ML (2003). Calcium-dependent interaction of calcineurin with Bcl-2 in neuronal tissue. *Neuroscience* **117**: 541–555.
 32. Girault, I, Rougier, N, Chesné, C, Lidereau, R, Beaune, P, Bieche, I *et al.* (2005). Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction. *Drug Metab Dispos* **33**: 1803–1810.
 33. Girault, I, Lerebours, F, Tozlu, S, Spyrtatos, F, Tubiana-Hulin, M, Lidereau, R *et al.* (2002). Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas. *J Steroid Biochem Mol Biol* **82**: 323–332.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>